keyword
MENU ▼
Read by QxMD icon Read
search

adjuvant treatment breast cancer

keyword
https://www.readbyqxmd.com/read/29223989/geographic-variation-of-adjuvant-breast-cancer-therapy-initiation-in-the-united-states-lessons-from-medicare-part-d
#1
John A Charlson, Emily L McGinley, Ann B Nattinger, Joan M Neuner, Liliana E Pezzin
Background: Drug utilization under Medicare Part D varies significantly by geographic region. This study examined the extent to which geographic variation in Part D plan characteristics contributes to the variation in choice of initial endocrine therapy agent among women with incident breast cancer. Methods: Two-stage multivariate regression analyses were applied to the 16,541 women identified from Medicare claims as having incident breast cancer in 2006-2007. The first stage determined the effect of state of residence on the probability of having an aromatase inhibitor (AI), as opposed to tamoxifen, as initial endocrine therapy...
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29223481/can-breast-cancer-patients-with-her2-dual-equivocal-tumours-be-managed-as-her2-negative-disease
#2
Yiwei Tong, Xiaosong Chen, Xiaochun Fei, Lin Lin, Jiayi Wu, Ou Huang, Jianrong He, Li Zhu, Weiguo Chen, Yafen Li, Kunwei Shen
BACKGROUND: Increasing human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC)/fluorescence in situ hybridisation (FISH) dual-equivocal breast tumours are reported after the 2013 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline update. The aim of this study is to investigate the clinico-pathologic characteristics, treatment patterns and disease outcome of these patients with HER2 dual-equivocal tumours. PATIENTS AND METHODS: Patients with HER2 IHC 2+ and available FISH results were retrospectively analysed from the Comprehensive Breast Health Center, Shanghai Ruijin Hospital...
December 7, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29221345/a-rare-mixed-breast-cancer-of-intraductal-and-solid-papillary-with-tubular-carcinoma-histotypes-in-a-young-woman
#3
Xiaohui Zhang, Jie Shi, Yidong Zhou, Feng Mao, Yan Lin, Jinghong Guan, Zhiyong Liang, Qiang Sun
Mixed breast cancer, especially of uncommon breast cancer histotypes, is rare, limiting our understanding of the disease and influencing diagnostic and management outcomes. We report a case of mixed breast cancer, with features of intraductal and solid papillary and tubular carcinomas, which appeared in a young patient. Physical examination, ultrasonography, molybdenum target mammography, and histopathology were performed for a definitive diagnosis. Tumor resection followed by radiotherapy and adjuvant chemotherapy was selected as the therapeutic strategy, and the patient was followed up thrice post treatment...
September 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29214842/trastuzumab-emtansine-determining-its-role-in-management-of-her2-breast-cancer
#4
Deborah B Doroshow, Patricia M LoRusso
Trastuzumab emtansine is an antibody-drug conjugate comprised of the anti-HER2 monoclonal antibody trastuzumab linked to DM1 (emtansine), a potent cytotoxic maytansinoid derivative, by a stable linker. This structure results in improved tumor-directed cytotoxicity in HER2+ breast cancer with reduced systemic toxicities, particularly the cardiac toxicities associated with single agent trastuzumab. Phase III trials have demonstrated improved progression-free and overall survival in heavily pretreated patients with advanced HER2+ breast cancer, with an acceptable toxicity profile...
December 7, 2017: Future Oncology
https://www.readbyqxmd.com/read/29212856/tamoxifen-resistance-in-breast-cancer-is-regulated-by-the-ezh2-er%C3%AE-greb1-transcriptional-axis
#5
Yanming Wu, Zhao Zhang, Mauro E Cenciarini, Cecilia J Proietti, Matias F Amasino, Tao Hong, Mei Yang, Yiji Liao, Huai-Chin Chiang, Virginia Kaklamani, Rinath Jeselsohn, Ratna K Vadlamudi, Tim H-M Huang, Rong Li, Carmine De Angelis, Xiaoyong Fu, Patricia V Elizalde, Rachel Schiff, Myles Brown, Kexin Xu
Resistance to cancer treatment can be driven by epigenetic reprogramming of specific transcriptomes in favor of the refractory phenotypes. Here we discover that tamoxifen resistance in breast cancer is driven by a regulatory axis consisting of a master transcription factor, its cofactor and an epigenetic regulator. The oncogenic histone methyltransferase EZH2 conferred tamoxifen resistance by silencing the expression of the estrogen receptor α (ERα) cofactor GREB1. In clinical specimens, induction of DNA methylation of a particular CpG enriched region at the GREB1 promoter negatively correlated with GREB1 levels and cell sensitivity to endocrine agents...
December 6, 2017: Cancer Research
https://www.readbyqxmd.com/read/29211792/the-prognostic-role-of-tumor-size-in-early-breast-cancer-in-the-era-of-molecular-biology
#6
Anaid Anna Kasangian, Giorgio Gherardi, Elena Biagioli, Valter Torri, Anna Moretti, Elena Bernardin, Andrea Cordovana, Gabriella Farina, Annalisa Bramati, Sheila Piva, Maria Chiara Dazzani, Emanuela Paternò, Nicla Maria La Verde
BACKGROUND: The prognosis of early breast cancer (EBC) depends on patient and tumor characteristics. The association between tumor size, the largest diameter in TNM staging, and prognosis is well recognized. According to TNM, tumors classified as T2, could have very different volumes; e.g. a tumor of 2.1 cm has a volume of 4500 mm3, while a tumor of 4.9 cm has a volume of 60.000 mm3 even belonging to the same class. The aim of the study is to establish if the prognostic role of tumor size, expressed as diameter and volume, has been overshadowed by other factors...
2017: PloS One
https://www.readbyqxmd.com/read/29209569/resistance-to-her2-targeted-anti-cancer-drugs-is-associated-with-immune-evasion-in-cancer-cells-and-their-derived-extracellular-vesicles
#7
Vanesa G Martinez, Sadhbh O'Neill, Josephine Salimu, Susan Breslin, Aled Clayton, John Crown, Lorraine O'Driscoll
Neuromedin U (NmU) -a neuropeptide belonging to the neuromedin family- plays a substantial role in HER2-positive breast cancer, correlating with increased aggressiveness, resistance to HER2-targeted therapies and overall significantly poorer outcome for patients. However, the mechanism through which it exerts these effects remains unclear. To elucidate this, initially we used HER2-positive breast cancer cells stably over-expressing NmU. These cells and their released extracellular vesicles (EVs) had increased amounts of the immunosuppressive cytokine TGFβ1 and the lymphocyte activation inhibitor PD-L1...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/29207126/melatonin-enhances-the-apoptotic-effects-and-modulates-the-changes-in-gene-expression-induced-by-docetaxel-in-mcf%C3%A2-7-human-breast-cancer-cells
#8
Carolina Alonso-González, Javier Menéndez-Menéndez, Alicia González-González, Alicia González, Samuel Cos, Carlos Martínez-Campa
Results from clinical trials and multiple in vivo and in vitro studies point to melatonin as a promising adjuvant molecule with many beneficial effects when concomitantly administered with chemotherapy. Melatonin palliates side‑effects and enhances the efficacy of chemotherapeutic agents. However, the mechanisms through which melatonin regulates molecular changes induced by chemotherapeutic agents remain largely unknown. In this study, we demonstrated that melatonin enhanced the anti-proliferative and apoptotic responses to low doses of docetaxel in breast cancer cells...
November 28, 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/29205665/toxicity-of-docetaxel-carboplatin-and-trastuzumab-combination-as-adjuvant-or-neo-adjuvant-treatment-for-her2%C3%A2-positive-breast-cancer-patients-and-impact-of-colony-stimulating-factor-prophylaxis
#9
Juan Bayo, Victoria Aviñó, Fátima Toscano, Francisco Jiménez
While the docetaxel, carboplatin, and trastuzumab (TCH) regimen is one of the standard treatments in Her2-positive breast cancer, however, acute toxicities, especially those related to the high rate of neutropenia are consistently reported. Primary: To compare the toxicity of TCH in current clinical practice vs the toxicity observed in the pivotal study, comparing the toxicity in patients that received primary prophylaxis (PP) with colony-stimulating factors vs those that did not receive PP. Secondary: To describe the demographic and clinical characteristics of the study sample, as well as the adverse effects and survival...
December 5, 2017: Breast Journal
https://www.readbyqxmd.com/read/29205077/forty-years-of-landmark-trials-undertaken-by-the-danish-breast-cancer-cooperative-group-dbcg-nationwide-or-in-international-collaboration
#10
Bent Ejlertsen, Birgitte Vrou Offersen, Jens Overgaard, Peer Christiansen, Maj-Britt Jensen, Niels Kroman, Ann Søgaard Knoop, Henning Mouridsen
BACKGROUND: Over the past 40 years the Danish Breast Cancer Cooperative Group (DBCG) has made significant contributions to improve outcome and to make treatment of patients with early breast cancer more tolerable through nationwide and international trials evaluating loco-regional and systemic treatments. These trials have been instrumental to establish standards for the treatment of early breast cancer. METHODS: The DBCG 82 trials had a global impact by documenting that the significant gain in loco-regional recurrence from postmastectomy radiation added to systemic therapy was associated with a reduction in distant recurrence and mortality in high-risk pre- and postmenopausal patients...
December 5, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29204847/adjuvant-chemotherapeutic-treatment-of-1650-patients-with-early-breast-cancer-in-routine-care-in-germany-data-from-the-prospective-tmk-cohort-study
#11
Steffen Dörfel, Claus-Christoph Steffens, Dirk Meyer, Hans Tesch, Lisa Kruggel, Melanie Frank, Martina Jänicke, Norbert Marschner
BACKGROUND: Several regimens for which efficacy was established in randomized controlled trials are recommended in current treatment guidelines for early breast cancer. However, knowledge on use and effectiveness of commonly administered chemotherapeutic agents in real-life care and across all breast cancer subtypes is limited. METHODS: The prospective, multicentre German TMK cohort study (Tumour Registry Breast Cancer) recruited patients in 148 oncology outpatient-centres...
December 4, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29204519/cardiac-sparing-radiation-therapy-using-positioning-breast-shell-for-patients-with-left-sided-breast-cancer-who-are-ineligible-for-breath-hold-techniques
#12
Kurian Joseph, Heather Warkentin, Sunita Ghosh, Lee-Anne Polkosnik, Kent Powell, Matthew Brennan, Brad Warkentin, Johanna Jacobs, Khalifa Alkaabi, Susan Chafe, Keith Tankel, Zsolt Gabos, Hong-Wei Liu, Patricia Tai
Purpose: Patients with left-sided breast cancer (LSBC) are at increased risk of cardiac morbidity from adjuvant breast radiation therapy (ABRT). Breath-hold (BH) techniques substantially reduce the radiation received by heart during radiation therapy for LSBC. However, a subset of patients with LSBC are ineligible for BH techniques due to an inability to breath-hold or because of other comorbidities. To reduce radiation to the heart, we routinely use a custom-made breast shell for the treatment of patients with LSBC who are ineligible for BH techniques...
October 2017: Advances in Radiation Oncology
https://www.readbyqxmd.com/read/29202842/preclinical-and-clinical-aspects-of-tnf-%C3%AE-and-its-receptors-tnfr1-and-tnfr2-in-breast-cancer
#13
REVIEW
Isela Martínez-Reza, Lorenza Díaz, Rocío García-Becerra
Breast cancer is the most common malignancy in women and a public health problem worldwide. Breast cancer is often accompanied by an inflammatory process characterized by the presence of proinflammatory cytokines such as tumor necrosis factor (TNF-α), which has important implications in the course of the disease. Inflammation has been described primarily as a favorable environment for tumor development. However, under certain conditions TNF-α can promote signals for activation, differentiation, survival or cell death, so the study of the variants of this cytokine, its receptors, the presence of polymorphisms and its implication in different phenotypes of breast cancer is necessary...
December 4, 2017: Journal of Biomedical Science
https://www.readbyqxmd.com/read/29202645/influence-of-specific-comorbidities-on-survival-after-early-stage-breast-cancer
#14
Marianne Ewertz, Lotte Holm Land, Susanne Oksbjerg Dalton, Deirdre Cronin-Fenton, Maj-Britt Jensen
BACKGROUND: While comorbidity indices are useful for describing trends in survival, information on specific comorbidities is needed for the clinician advising the individual breast cancer patient on her treatment. Here we present an analysis of overall survival, breast cancer-specific mortality, and effect of medical adjuvant treatment among breast cancer patients suffering from 12 major comorbidities compared with breast cancer patients without comorbidities. MATERIAL AND METHODS: The study population was identified from the Danish Breast Cancer Cooperative Group and included 59,673 women without prior cancer diagnosed with early-stage breast cancer in Denmark from 1990 to 2008 with an estimated median potential follow-up of 14 years and 10 months...
December 5, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29202630/concurrent-new-drug-prescriptions-and-prognosis-of-early-breast-cancer-studies-using-the-danish-breast-cancer-group-clinical-database
#15
Deirdre Cronin-Fenton, Timothy L Lash, Thomas P Ahern, Per Damkier, Peer Christiansen, Bent Ejlertsen, Henrik T Sørensen
BACKGROUND: Myriad reports suggest that frequently used prescription drugs alter the viability of breast cancer cells in pre-clinical studies. Routine use of these drugs, therefore, may impact breast cancer prognosis, and could have important implications for public health. METHODS: The Danish Breast Cancer Group (DBCG) clinical database provides high-quality prospectively collected data on breast cancer diagnosis, treatment, and routine follow-up for breast cancer recurrence...
December 5, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29201277/pre-operative-endocrine-therapy
#16
REVIEW
Laura M Arthur, Arran K Turnbull, Lucy R Khan, J Michael Dixon
Purpose of Review: Pre-operative endocrine therapy can be used to down-stage large or locally advanced breast cancers in ER+ disease. In the last four decades, it has evolved from a treatment perceived as an alternative to surgery for those too unfit to undergo surgery or chemotherapy, to the present day where it is a valuable and valid option in the treatment of postmenopausal women with ER-rich (Allred score 7-8, or > 50% staining for ER) breast cancer. Recent Findings: Emerging data from the metastatic setting is translating into neoadjuvant trials, utilising dual endocrine targeting or combinations of endocrine agents and other targeted drugs, including those acting against components of the PI3K pathway and the cell cycle...
2017: Current Breast Cancer Reports
https://www.readbyqxmd.com/read/29196963/serum-lipid-and-bone-metabolism-effects-of-toremifene-vs-letrozole-as-adjuvant-therapy-for-postmenopausal-early-breast-cancer-patients-results-of-a-multicenter-open-randomized-study
#17
Tadahiko Shien, Hiroyoshi Doihara, Nobuaki Sato, Keisei Anan, Kansei Komaki, Keisuke Miyauchi, Yasuhiro Yanagita, Tomomi Fujisawa, Shoshu Mitsuyama, Chizuko Kanbayashi, Mikihiro Kusama, Morihiko Kimura, Hiromitsu Jinno, Muneaki Sano, Tadashi Ikeda
A prospective randomized phase II trial was conducted to evaluate the time course effects of toremifene (TOR) and letrozole (LET), as adjuvant hormone therapy, on serum lipid profiles and bone metabolism in estrogen receptor (ER)-positive, postmenopausal breast cancer patients.Fifty-four postmenopausal breast cancer patients [ER positive, HER2 negative, T1-2, node metastases (n = 0-3), M0] who had undergone curative resection were enrolled. They were randomized to receive either TOR 40 mg/day or LET 2...
December 1, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29194077/advances-in-targeting-her2-positive-breast-cancer
#18
Nadia Harbeck
PURPOSE OF REVIEW: Breast cancer is the most common malignancy in women and HER2-positive disease comprises about 15% of all breast cancer cases. Over the last few years, substantial advances have been made in treatment of early breast cancer (EBC) and advanced (ABC) HER2-positive (HER2+) breast cancer. The present review summarizes the major publications on HER2+ breast cancer in the year 2017 and discusses their clinical relevance. RECENT FINDINGS: The clinically most relevant data in 2017 relates to the EBC setting...
November 30, 2017: Current Opinion in Obstetrics & Gynecology
https://www.readbyqxmd.com/read/29193984/population-based-study-to-determine-the-health-system-costs-of-using-the-21-gene-assay
#19
Nicole Mittmann, Craig C Earle, Stephanie Y Cheng, Jim A Julian, Farah Rahman, Soo Jin Seung, Mark N Levine
Purpose The 21-gene assay Oncotype Dx (Genomic Health, Redwood City, CA) test is used to aid the decision about chemotherapy in patients with hormone receptor-positive breast cancer who received endocrine therapy. Economic studies to support test adoption used decision-analytic models with assumptions and data derived from disparate sources. The objective was to evaluate whether the 21-gene assay test resulted in an overall cost expense or saving to the health system. Patients and Methods One thousand participants enrolled in a field evaluation study, were linked to population-level health system administrative databases, and were observed for 20 months...
December 1, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29190955/concurrent-administration-of-trastuzumab-and-anthracyclines-as-adjuvant-regimen-for-her2-positive-breast-cancer-a-randomised-controlled-trial
#20
Songjie Shen, Ying Xu, Yidong Zhou, Feng Mao, Jinghong Guan, Qiang Sun
Background: The regimen of concurrent administration of trastuzumab and anthracyclines in the adjuvant treatment of breast cancer has never been evaluated prospectively for fear of cardiac toxicity. Methods: Patients with HER2-positive operable breast cancer were randomised to receive adjuvant treatment with concurrent or sequential administration of trastuzumab and anthracyclines. Cardiac monitoring was scheduled at baseline and every 3 months after the first dose of trastuzumab...
November 3, 2017: Oncotarget
keyword
keyword
116441
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"